PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Prasugrel - Prevention of atherothrombotic events - Acute Coronary Syndrome
PAD Profile : Prasugrel - Prevention of atherothrombotic events - Acute Coronary Syndrome
Keywords :
ACS, dual antiplatelet therapy, triple antiplatelet therapy, DAPT
Brand Names Include :
Efient
Traffic Light Status
Status 1 of 1.
Status :
Blue
Important
Formulations :
- Tablets
Important Information :
Restricted to cardiology consultants. Clopidogrel is the preferred option.
Specialist initiation and at least one month supply before transfer to primary care
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (Local)
01 July 2023
NICE Technology Appraisal
NICE TA317 - Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
Committee Recommendations
Date
Committee Name
Narrative
29 July 2020
Surrey Heartlands Medicines Safety Committee (MSC)
Co-prescribing of antiplatelets / anticoagulants may be requested by a specialist in a number of scenarios.
The Medicines safety Group have produced an aide memoire to list the information that must be available to the primary care clinican to support the safe prescribing of dual / triple therapies in primary care.
See below for document: "Dual antiplatelet-anticoagulant therapy - Aide memoire for managing hospital requests"
01 February 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
A scheduled review of the expired information sheet has taken place and was approved at PCN. The place in therapy of antiplatelets in Acute Coronary Syndrome had previously been discussed by the PCN in January 2013 and the policy statement from those discussions still stands. See below for approved BLUE information sheet and policy statement (PCN 42-2013) from previous discussions.
Associated BNF Codes
02. Cardiovascular System
02.09.00. Antiplatelet drugs